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ABSTRACT
The pentose phosphate pathway is a fundamental metabolic pathway that provides 
cells with ribose and NADPH required for anabolic reactions — synthesis of nucleotides 
and fatty acids — and maintenance of intracellular redox homeostasis. It plays a key 
role in tumor metabolic reprogramming and has been reported to be deregulated in 
different types of tumors. Herein, we silenced the most important enzymes of this 
pathway — glucose-6-phosphate dehydrogenase (G6PD) and transketolase (TKT) — in 
the human breast cancer cell line MCF7. We demonstrated that inhibition of G6PD, the 
oxidative branch-controlling enzyme, reduced proliferation, cell survival and increased 
oxidative stress. At the metabolic level, silencing of both enzymes reduced ribose 
synthesis. G6PD silencing in particular, augmented the glycolytic flux, reduced lipid 
synthesis and increased glutamine uptake, whereas silencing of TKT reduced the 
glycolytic flux. Importantly, we showed using breast cancer patient datasets that 
expression of both enzymes is positively correlated and that high expression levels 
of G6PD and TKT are associated with decreased overall and relapse-free survival. 
Altogether, our results suggest that this metabolic pathway could be subjected to 
therapeutic intervention to treat breast tumors and warrant further investigation.
INTRODUCTION
Cancer cells need to reprogram their metabolism 
to fulfill specific metabolic requirements and to achieve 
a fully malignant phenotype [1, 2]. The so-called 
tumor metabolic reprogramming is aimed to meet the 
bioenergetics demands of cancer cells, providing them 
with precursors for the synthesis of macromolecules 
and maintaining redox homeostasis [3]. One of the most 
important metabolic pathways that participate in these 
processes is the pentose phosphate pathway (PPP), which 
synthesizes the nucleotide precursor ribose-5-phosphate 
and produces the reduced form of the nicotinamide 
adenine dinucleotide phosphate (NADPH), an essential 
cofactor required for the synthesis of lipids and the 
maintenance of the antioxidant systems, such as the 
reduced glutathione pool. Thus, it has been proposed that 
the activation of the PPP could be regarded as a hallmark 
of cell transformation [4].
The pentose phosphate pathway is divided into the 
oxidative and the non-oxidative branches. The oxidative 
branch (ox-PPP) catalyzes the irreversible transformation 
of glucose-6-phosphate (G6P) into ribulose-5-phosphate 
(Ri5P) with the subsequent production of NADPH 
and CO2. The non-oxidative branch (nonox-PPP) is a 
reversible pathway that interconverts glyceradehyde-3-
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phosphate (G3P), erythrose-4-phosphate (E4P), xylulose-
5-phosphate (X5P), ribose-5-phosphate (R5P), fructose-
6-phosphate (F6P) and sedoheptulose-7-phosphate (S7P), 
contributing to the synthesis of Ri5P and the redirection of 
the excess of this metabolite towards glycolysis. Glucose-
6-phosphate dehydrogenase (G6PD) and transketolase 
(TKT) are considered as the key enzymes of the oxidative 
and the non-oxidative branches, respectively.
G6PD is a fundamental enzyme for protecting cells 
against oxidative stress [5–8] and it is involved in some 
biosynthetic processes, such as lipogenesis, by providing 
NADPH [9, 10]. Its expression and activity have been 
reported to be regulated by some of the most important 
oncogenes such as k-ras [11] or p53 [2, 12] and it is one 
of the core enzymes involved in the response to oxidative 
stress coordinated by NRF2, a critical transcription factor 
reported to play a key role in tumorigenesis [9, 13, 14]. 
Compared to normal cells, malignant cells display higher 
levels of endogenous oxidative stress both in vitro and 
in vivo [15–17]. Particularly, breast tumors are 
characterized by persistent ROS generation [18, 19] 
and markers of constitutive oxidative stress have 
been detected in patient samples of breast carcinomas 
[20–22]. Consequently, breast tumors also display greater 
dependence on ROS detoxification systems, which 
increases gradually as the tumor progresses and becomes 
metastatic [23]. Under high oxidative stress conditions, 
G6PD activity increases to produce NADPH needed 
for the generation of reduced glutathione. Under these 
conditions, TKT converts the excess of R5P to G3P and 
F6P by a series of reactions. In this way, F6P can then be 
converted to G6P to replenish the ox-PPP for additional 
NADPH generation while G3P can be metabolized 
through further steps of glycolysis [10]. In cancer cells, 
given their rapidly dividing nature, TKT activity is 
increased to produce additional R5P from F6P and G3P by 
reverse reactions. In fact, it has been demonstrated that in 
rapidly growing cancer cells, 80% of ribonucleotides are 
produced through the nonox-PPP [24]. TKT activity has 
been reported to have a high control coefficient of tumor 
growth in mice with Ehrlich’s ascites tumor [25] and to 
be increased in (pre)neoplasic lesions in rat liver [26] and 
pancreatic adenocarcinoma, where the nonox-PPP is the 
main pathway responsible for riboneogenesis [24, 27]. 
Similar to G6PD, TKT is also overexpressed with NRF2 
activation to assure sufficient NADPH and nucleotide 
levels. Well-known oncogenes such as K-Ras, B-Raf, 
Myc and PI3K/Akt are indirect regulators of TKT, since 
they take role in expression of NRF2 [9, 13]. Altogether, 
both G6PD and TKT are crucial enzymes in modulating 
the tumor metabolic phenotype. 
The purpose of this study is to investigate the 
function of these two enzymes in breast cancer cell 
metabolism and to explore their potential as therapeutic 
targets. In our study, we chose breast cancer cells because 
they heavily rely upon PPP to manage oxidative stress 
and survive [10, 28]. Particularly, we selected MCF7 cells 
because they reportedly show increased expression of 
G6PD compared with the near-normal breast cancer cell 
line MCF10 [29]. First, G6PD and TKT were silenced in 
the breast cancer cell line MCF7 and the impact on cell 
proliferation, survival and cell cycle was assessed. Second, 
the metabolic effects of the inhibitions of these two 
enzymes were evaluated by [13C]-assisted metabolomics 
and metabolic flux analysis. Finally, the translational 
relevance of our findings was evaluated by survival and 
gene expression correlation analyses conducted on breast 
cancer patient datasets.
RESULTS
G6PD inhibition reduces cell proliferation and 
survival
To understand the biological and metabolic role of 
these two enzymes in breast cancer, we separately silenced 
TKT (siTKT) and G6PD (siG6PD) in the breast cancer 
cell line MCF7 by using specific small interference RNAs 
(siRNA). As shown in Figure 1A, both enzymes were 
effectively inhibited at the mRNA level by more than 
75%, and the specific enzyme activities were reduced 
approximately 50% in both cases (Figure 1B–1C). Since 
PPP is an anabolic pathway that plays a fundamental role 
in cell growth, we examined the role of TKT and G6PD 
in proliferation and survival by performing proliferation 
experiments in combination with propidium iodide (PI) 
staining. G6PD silencing reduced cell proliferation 
(Figure 2A) and increased cell death as reported by 
an increase in the PI-positive cell population (Figure 
2B). In contrast, no differences in proliferation and cell 
viability were detected when TKT was silenced (Figure 
2A–2B). G6PD and TKT enzymatic activities have 
been reported to be enhanced during late G1 and S cell 
cycle phases and specific upregulation of the oxidative 
branch has been demonstrated in colon cancer cells [30]. 
Moreover, knowing that one of the essential roles of PPP 
is to provide ribose for cell proliferation, we hypothesized 
that inhibition of these enzymes could affect cell cycle 
progression. We found that both G6PD and TKT silencing 
induced a cell cycle arrest in G1 phase and a subsequent 
decrease in the percentage of cells in S phase (Figure 2C). 
This finding was also corroborated by an increase in the 
expression of cyclin E, a cell cycle-dependent protein that 
reaches its maximal expression in late G1 (Figure 2D).
PPP inhibition modulates glycolytic flux and 
enhances glutaminolysis
To obtain further insight into the metabolic role of 
PPP in breast cancer cell metabolism, we performed a [13C]-
assisted metabolomics experiment. Cells were transfected 
with the corresponding siRNAs and cultured in medium 
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containing 50% of [1,2-13C2]-glucose. We first wanted to 
know whether the inhibition of G6PD and TKT altered the 
consumption and release (CORE) of the most abundant 
metabolites. TKT silencing decreased the rate of glucose 
consumption concomitantly with a decrease in the rate of 
lactate production (Figure 3A). On the contrary, silencing of 
G6PD did not affect glucose consumption, rather a significant 
increase in lactate production was observed. One of the most 
striking findings was that G6PD silencing doubled glutamine 
consumption and notably increased the production rate of 
glutamate. Conversely, when TKT was silenced no changes 
were observed in glutamine consumption but a decrease in 
the production of glutamate was detected. 
Next, we sought to understand the mechanism 
for the increase in lactate production in G6PD-silenced 
cells. In cancer cells, lactate is primarily produced 
from glucose. When cells are cultured with [1,2-13C2]-
glucose, the isotopologue distribution of lactate allows 
the estimation of the glucose-derived carbon flow. Using 
the rate of lactate production in combination with its 
isotopologue distribution (Supplementary Figure 1), 
the glycolytic flux—the rate of lactate production 
from glucose via glycolysis—can be estimated. Thus, 
when TKT was silenced, we observed a decrease in 
the glycolytic flux (Figure 3B). Strikingly, despite not 
observing changes in glucose consumption, silencing 
of G6PD promoted an increase in this flux. This fact 
prompted us to investigate the fate of glucose in the 
different experimental conditions. Silencing of G6PD 
raised the proportion of glucose-derived carbons dedicated 
to lactate, whereas this proportion did not change when 
TKT was silenced (Figure 3C). Also, it is noteworthy that 
silencing of TKT and G6PD reduced the percentage of m2 
labelled alanine (Figure 3D).
Silencing of TKT and G6PD reduces ribose 
synthesis
TKT and G6PD are the key enzymes of PPP and 
participate in the synthesis of ribose. Hence, we aimed 
to understand the impact of TKT and G6PD silencing 
on the PPP by analyzing the isotopologue distribution of 
ribose from RNA. Silencing of TKT and G6PD reduced 
in a similar extent the synthesis of ribose as indicated by 
the decrease of the [13C] enrichment of this metabolite 
(Figure 3E). The use of [1,2-13C2]-glucose allowed us 
Figure 1: Silencing of TKT and G6PD in MCF7 cells. (A) TKT and G6PD mRNA levels three days after transfection of non-
targeting siRNA (siNEG) or siRNA targeting TKT (siTKT) or G6PD (siG6PD). (B) TKT activity five days after siTKT transfection. 
(C) G6PD activity after siG6PD transfection. In all plots values are expressed as fold change versus siNEG and bars represent mean 
(n = 3) ± SD.
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to discriminate between the use of the oxidative and the 
nonoxidative branches of the PPP in the synthesis of 
ribose (ox-PPP and nonox-PPP, respectively). [1,2-13C2]-
glucose can be metabolized through either the ox-PPP or 
the nonox-PPP branch, producing m1 or m2 13C-labelled 
ribose, respectively. In our experiment, we observed that 
silencing of TKT caused a prominent decrease in the 
utilization of the nonox-PPP (m2 ribose) and slightly 
increased the flux through the ox-PPP (m1 ribose) (Figure 
3F). On the contrary, silencing of G6PD reduced the ox-
PPP flux and caused a marginal increase in the nonox-
PPP flux. These changes altered the ox-PPP/nonox-PPP 
ratio, which is measured by the ratio of m1 to m2 ribose. 
Silencing of TKT dramatically increased the ox-PPP/
nonox-PPP ratio whereas silencing of G6PD resulted in a 
modest reduction (Figure 3G).
G6PD silencing increases ROS levels and reduces 
fatty acid synthesis
The ox-PPP is a major source of NADPH, an 
essential cofactor in ROS detoxification and lipid 
synthesis. As redox homeostasis plays an important role 
in breast cancer progression, we assessed the effect of 
TKT and G6PD silencing on ROS levels. Our results 
clearly showed that silencing of G6PD increased ROS 
levels whereas no changes were detected when TKT was 
silenced (Figure 4A).
It has also been documented that cancer cells 
display an increased requirement of lipids to sustain rapid 
proliferation [31]. Therefore, we studied the impact of 
TKT and G6PD silencing on lipid synthesis from glucose 
by analyzing the isotopologue distribution of palmitate and 
stearate. Cells were transfected and cultured in medium 
containing 50% of [1,2-13C2]-glucose. Remarkably, 
silencing of G6PD reduced the synthesis of palmitate 
and stearate as indicated by lower 13C enrichment in 
these fatty acids (Figure 4B–4C), whereas no changes 
in the enrichment of either of them were detected when 
TKT was silenced. We have previously demonstrated 
that silencing of G6PD increases the amount of glucose 
dedicated to lactate production. Therefore, the observed 
reduction in lipid synthesis was likely due to a decreased 
entry of pyruvate into mitochondria. To better understand 
this aspect, we next used the isotopologue distribution of 
palmitate to calculate the percentage of 13C-acetyl-CoA and 
Figure 2: Role of PPP enzymes TKT and G6PD in cell proliferation, survival and cell cycle. (A) Effect of TKT and G6PD 
silencing on proliferation six days after transfection expressed as percentage of siNEG. (B) Effect of TKT and G6PD silencing on cell death 
six days after transfection (percentage of PI-positive cells). Bars in A and B represent mean (n = 2) ± SEM for TKT and mean (n = 5) ± 
SEM for G6PD. (C) Effect of TKT and G6PD silencing on cell cycle progression five days after siRNA transfection. The percentages of 
cells in each phase are depicted as mean (n = 3) ± SD. (D) Cyclin E and β-actin (loading control) protein levels were analyzed four days 
after siRNA transfection. 
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the percentage of glucose dedicated to fatty acid synthesis. 
Thus, when G6PD was silenced, we observed a decrease in 
the percentage of 13C-acetyl-CoA, indicating a decreased 
flux of glucose-derived carbons into the mitochondria 
(Figure 4D). Consequently, we also found a reduction in 
the percentage of glucose dedicated to the synthesis of 
acetyl-CoA when G6PD was silenced (Figure 4E). Taken 
together, these results highlight the importance of the ox-
PPP as a source of NADPH and the fine regulation that it 
exerts on redox balance and lipid synthesis.
High expression of G6PD and TKT show positive 
correlation and is associated with poor patient 
outcome
TKT and G6PD have been postulated as relevant 
enzymes in tumor cells by different studies, but little 
is known about the impact of the expression level of 
these enzymes on disease progression and survival. We 
surveyed three independent breast cancer gene expression 
datasets to explore the relation between TKT and G6PD 
Figure 3: Metabolic effects of TKT and G6PD silencing. [13C]-assisted metabolomics experiment was performed by replacing 
culture media by fresh media containing 50% of [1,2-13C2]-glucose four days after siRNA transfection. Cells were incubated with the tracer 
for 24h and extracellular fluxes and isotopologue distribution of different metabolites were determined. (A) CORE (consumption and 
release) metabolic profile showing rates of consumption of glucose (Glc) and glutamine (Gln) and release of lactate (Lac) and glutamate 
(Glu). (B) Flux of production of lactate from glucose via glycolysis. (C) Proportion of consumed glucose dedicated to either production of 
lactate or other uses. (D) Levels of m2 13C-alanine in media. (E) Total 13C-labeled ribose from RNA. (F) Isotopologue distribution of ribose 
from RNA. (G) Ratio of m1 13C-ribose to m2 13C-ribose as an indicator of the oxidative vs. non-oxidative PPP activity. In all cases values 
represent mean (n = 3) ± SD.
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expression and patient outcome. Kaplan–Meier analyses 
revealed a decreased overall and relapse-free survival 
in patients with high expression levels of TKT or 
G6PD in at least two out of the three datasets analyzed 
(Figure 5). Additionally, we were also interested in 
understanding how the expression of these two enzymes 
was coordinated. We performed a correlation analysis for 
the expression of TKT and G6PD in the three datasets. As 
shown in Figure 6, TKT and G6PD expression showed 
a strong positive correlation in two of the datasets 
(GSE20685 and GSE3494) and modest but significant 
correlation in the third one (GSE7390). 
DISCUSSION 
The aim of this study was to provide a better 
understanding of the role of PPP enzymes TKT and 
G6PD in breast tumors. Herein, we have first shown that 
silencing of G6PD reduces cell proliferation, induces cell 
death and promotes cell cycle arrest, whereas silencing of 
TKT also induces cell cycle arrest but does not seem to 
affect any of the other processes. We next demonstrated 
that silencing of G6PD increases glycolytic flux, 
glutamine consumption and ROS levels, and decreases 
glucose-derived synthesis of acetyl-CoA, palmitate and 
stearate. On the contrary, TKT silencing reduces glycolytic 
flux and has no detectable consequences on any of the 
other processes. We finally provided strong evidence to 
support the fact that high expression of TKT and G6PD 
is associated with poor outcome in breast cancer patients.
G6PD has been previously reported to be important 
for tumor growth and for antioxidant defense [33–35], 
although the exact mechanism by which it is important in 
the proliferation of breast cancer cells is still unclear. The 
high dependency of the MCF7 cell line on G6PD is clearly 
supported by the fact that by only inhibiting 50% of G6PD 
enzymatic activity a 35% decrease in cell proliferation was 
observed. Despite the fact that G6PD is the key enzyme 
in the ox-PPP, we have demonstrated that the impact of 
G6PD silencing on ribose synthesis is low. However, G6PD 
silencing substantially increased ROS levels, suggesting that, 
in MCF7 cells, G6PD is crucial for redox homeostasis but 
might be dispensable for ribose synthesis. The metabolic 
reaction catalyzed by G6PD is one of the major sources of 
NADPH in the cell, which is used for balancing intracellular 
oxidative stress [36, 37]. It is widely accepted that most 
tumors deal with increased levels of ROS, leading to 
intracellular conditions of high oxidative stress [18, 38]. 
Collectively, it is then plausible that, in our study, cell death 
induced by G6PD silencing is due to the deregulation of ROS 
homeostasis. The reduced availability of NADPH could also 
explain the decrease observed in fatty acid synthesis, which 
may further contribute to the reduction in cell proliferation.
Although G6PD had the greatest impact on cell 
proliferation and ROS levels, it is worth noting that 
silencing of TKT had the highest impact on pathway-
Figure 4: Role of PPP enzymes in ROS levels and lipid synthesis. (A). ROS levels five days after transfection. Bars represent 
mean (n = 3) ± SEM. (B) Total 13C-labeled palmitate and (C) stearate. (D) Estimated fraction of 13C-acetyl-CoA depicted as percentage 
of the total pool. (E) Percentage of glucose dedicated to the synthesis of acetyl-CoA estimated using the fraction of 13C-acetyl-CoA in 
combination with the maximal theoretical enrichment of acetyl-CoA from glucose. Data shown in figures D and E was calculated as 
described in Boren et al 2003 [32]. Bars represent mean (n = 3) ± SD. 
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specific ribose synthesis. The level of total 13C-labelled 
ribose was similarly decreased in both TKT- and G6PD-
silenced cells, but TKT showed a greater regulatory 
capacity over the nonox-PPP than G6PD did over the ox-
PPP. This fact could be related to the protein level of each 
enzyme in the cell. It has been reported that G6PD usually 
functions at around 2% of its total maximum enzymatic 
rate [4]. This fact suggests that the concentration of the 
enzyme could be in excess and its inhibition would have a 
low impact on the synthesis of ribose. This is corroborated 
by the fact that 50% inhibition of G6PD enzymatic activity 
provoked only a slight decrease in m1 ribose. On the 
contrary, our results indicated that TKT probably works 
at its maximum enzymatic rate, since 50% inhibition of 
the enzyme decreased m2 ribose in the same proportion. 
Interestingly, these results showed that TKT inhibition 
Figure 5: Survival analysis of breast cancer patients associated to the expression of TKT and G6PD. Kaplan–Meier 
survival analysis showing relapse-free and overall survival for breast cancer patients with high and low expression levels of G6PD or TKT 
in three independent datasets. p-values of log-rank test are depicted in each plot. 
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also increased m1 ribose, which could be due either to 
the impossibility of reintroducing ribose synthesized by 
the ox-PPP into glycolysis or to a compensatory activation 
of the flux through the ox-PPP, resulting in accumulation 
of m1 ribose. Taken together, these findings suggest that 
although both oxidative and nonoxidative PPP pathways 
are tightly connected, the functions of maintenance of 
ROS homeostasis and synthesis of ribose may be partially 
decoupled.
In our study, we have also observed that TKT 
and G6PD silencing modified the glycolytic flux in an 
opposite manner. Silencing of G6PD did not change 
glucose consumption but rather notably increased lactate 
production from glucose via glycolysis, indicating a 
reduction in the flux of glucose-derived carbons into 
mitochondria and other biosynthetic pathways, as 
suggested by the decrease in the percentage of m2 alanine. 
This observation could be explained on the basis of HIF 
(Hypoxia Inducible Factor) activation. The increase 
in ROS levels caused by G6PD inhibition can stabilize 
and activate HIF-dependent signaling pathway [39, 40], 
which in turn upregulates glycolysis and diverts pyruvate 
away from mitochondria by inactivation of the pyruvate 
dehydrogenase complex [41, 42]. This mechanism could 
fully explain the increase in the percentage of glucose 
dedicated to lactate production, the decrease in the 
synthesis of glucose-derived acetyl-CoA and the reduction 
in the contribution of glucose to lipid synthesis. 
One of the most striking findings in this study is the 
connection between PPP and glutaminolysis. Glutamine 
is a major carbon and nitrogen source that participates in 
bioenergetics (synthesis of ATP), defense against oxidative 
stress (provides carbons for glutathione synthesis and 
fuels NADPH-producing reactions) and production of 
macromolecules (lipids and other amino acids) [43]. 
Hence, the increase in the rate of glutamine uptake 
displayed by G6PD-silenced cells could be indicative of 
a response mechanism to provide carbons for NADPH-
generating mitochondrial enzymatic reactions, such 
as those catalyzed by the malic enzyme and isocitrate 
dehydrogenase [43]. Likewise, it could also be a response 
mechanism aimed to maintain ATP levels. It has been 
described that MCF7 cells produce 80% of total ATP 
through mitochondrial oxidative phosphorylation [44]. 
Therefore, it seems plausible that the reduction of the 
pyruvate influx into the mitochondria resulted in increased 
utilization of other mitochondrial substrates, such as 
glutamine, for ATP synthesis [45]. Another potential 
explanation arises from our observation that silencing 
of G6PD increased the glycolytic flux, increasing the 
concentration of intracellular lactate and consequently 
acidifying the intracellular milieu. It has been recently 
reported that acidosis enhances glutamine uptake and 
glutaminolysis by a mechanism partially dependent on 
p53 that involves upregulation of GLS2 [46]. Under these 
conditions, glutamine is utilized to increase NADPH 
production and counteract the increase in ROS associated 
with acidosis. 
Finally, we have also shown that high expression 
levels of G6PD and TKT correlate with poor overall 
and relapse-free survival in several breast cancer patient 
datasets. Previous studies in breast cancer tumors reported 
a gradual overactivation of PPP as the tumor progresses 
[23, 29]. Therefore, this fact alongside with our data 
suggests that the higher the expression of PPP enzymes, 
the higher the aggressiveness of the tumor. This also 
highlights not only the clinical relevance of this metabolic 
pathway, but also its potential use as a therapeutic target 
and biomarker of prognosis. In the same datasets, we 
have found that the expression of TKT and G6PD is 
positively correlated. PPP enzymes have been reported to 
be regulated by the transcription factor NRF2 [9]. NRF2 
exerts pleiotropic effects in cancer cells. It participates in 
the regulation of the antioxidant defense, chemoresistance, 
tumorigenesis and tumor progression, in part by promoting 
anabolic reactions such as those catalyzed by TKT and 
G6PD. Inactivating mutations and overexpression of 
sequestrating proteins of the NRF2 negative regulator 
KEAP1 have been found in breast cancer, resulting in high 
protein levels of this transcription factor [47–49]. It is also 
noteworthy that PI3K-Akt pathway is frequently mutated 
in breast tumors [50] and other studies have reported 
that activation of this signaling pathway augments 
nuclear accumulation of NRF2 [9]. Collectively, all these 
Figure 6: Gene expression correlation analyses. Pearson’s correlation analysis showing gene expression levels of TKT and G6PD 
in breast cancer patients from three independent datasets. Pearson’s correlation coefficient (r) and p-values are shown for each analysis.
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observations suggest that the expression of TKT, G6PD 
and potentially the entire pathway could be coordinately 
regulated as part of a central metabolic reprogramming.
In conclusion, in this work we show that inhibition 
of PPP enzymes TKT and G6PD results in different 
metabolic phenotypes, and that overexpression of 
both enzymes correlate with poor patient prognosis. In 
particular, G6PD arises as an interesting candidate for 
therapeutic intervention, as it regulates key metabolic 
processes in tumor cells, such as synthesis of ribose, fatty 
acids and redox homeostasis. We believe that this study 
warrants further investigation to explore the potential of 




Breast cancer cell line MCF7 was purchased from 
ATCC and cultured following manufacturer’s instructions 
in MEM medium without phenol red (Gibco) containing 
10% Fetal Bovine Serum (FBS) (Sigma-Aldrich), 10 mM 
glucose (Sigma-Aldrich), 1 mM pyruvate (Biological 
Industries), 2 mM glutamine (Gibco), 0.1% antibiotic 
(Penicillin 10 Units/mL-Streptomycin 10 µg/mL, Gibco), 
0.01 mg/mL insulin (Sigma-Aldrich) and 1% non-essential 
amino acids (Biological Industries). 
siRNA transfection
MCF7 cells were transfected with siRNAs using 
Metafectene (Biontex) according to the manufacturer’s 
instructions. Briefly, 1 × 105 cells/well were seeded 
in 6-well plates and after 24h were transfected with 
60 nM of control siRNA (siNEG), siRNAs against TKT 
(siTKT) or G6PD (siG6PD). The siRNA sequences 
(Dharmacon) used were: siNEG, ON-TARGETplus 
Non-targeting siRNA D-001810-03-20 (sequence not 
provided by the manufacturer); siTKT, ON-TARGETplus 
J-004734-06-0010, GGAACUAGCCGCCAAUACA; 
siG6PD, ON-TARGETplus J-008181-06-0010, 
GAGAGUGGGUUUCCAGUAU.
Proliferation, viability and cell cycle
Proliferation and viability assays were performed by 
flow cytometry combining cell counting and propidium 
iodide (PI) staining. At the end of the experiment or 
as indicated elsewhere cells were trypsinized and 
resuspended in 500 µL of a solution consisted of 450 µL 
of complete media, 45 µL of Flow-Count Fluorospheres 
(Beckman Coulter) and 5 µL of 1 mg/mL PI solution. 
Flow cytometer was set to 1 × 104 fluorospheres cut-off 
and total cell number (PI-positive and PI-negative) was 
recorded. For cell cycle analysis, cells were collected 
and fixed with 70% cold ethanol prior to centrifugation 
and resuspension in PBS supplemented with 0.01% 
(v/v) Triton X-100, 1 mg/mL PI, and 0.2 mg/mL RNAse 
A (REAL Laboratories). Samples were analyzed by 
flow cytometry and cell cycle phase distribution was 
determined using FlowJo®.
Western blotting
Protein extracts were prepared using RIPA buffer 
supplemented with 1% protease inhibitor cocktail (Thermo 
Fisher Scientific Inc.), 1% phosphatase inhibitor cocktail 
(Thermo Fisher Scientific Inc.) and quantified by BCA 
assay. Equal amounts of protein were separated by SDS-
PAGE and transferred onto PVDF membrane (Bio-Rad 
Laboratories). After, membranes were blocked for 1h with 
5% skim milk in 0.1% Tween PBS and incubated with 
the specific primary antibodies overnight at 4°C. Then, 
membranes were treated with the appropriate secondary 
antibody for 1 h at room temperature. All blots were 
treated with Immobilon ECL Western Blotting Detection 
Kit Reagent (EMD Millipore) and developed after 
exposure to an autoradiography film (VWR International). 
The following antibodies were used: anti-cyclin E (HE12, 
Santa Cruz) and anti-actin (691001, Millipore).
RNA extraction and gene expression
RNA was extracted using Trizol® (Invitrogen) 
following the manufacturer’s instructions. Briefly, cells 
were treated with Trizol and the homogenates were 
mixed with chloroform and centrifuged. RNA was then 
precipitated from the aqueous phase with cold isopropanol 
and subsequent centrifugation. Next, the supernatant was 
removed and the RNA pellet was rinsed with 75% cold 
ethanol. After ethanol evaporation, RNA was resuspended 
in RNAse-free water and the concentration was 
determined using Nanodrop. Next, cDNA was synthesized 
using 1 µg of RNA, random primers (Roche) and M-MLV 
reverse transcriptase (Invitrogen) according to the 
manufacturer’s indications. Gene expression analyses 
were performed by qPCR (ABI Prism 7700 Sequence 
Detector System, Applied Biosystems) using Taqman® 
(Applied Biosystems) as per manufacturer’s instructions. 
The following probes were used: G6PD, Hs00166169_
m1; TKT, Hs00169074_m1; PPIA, Hs99999904_m1. 
Gene expression was quantified by the ΔΔCt method using 
PPIA as a reference gene.
ROS
Total intracellular ROS levels were determined 
by flow cytometry using H2DCFA probe (Invitrogen) 
following the manufacturer’s instructions. Briefly, cells 
were incubated with 5 µM H2DCFA in PBS for 30 min. 
After that, PBS was replaced by culture media and 
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cells were incubated for 15 min at 37°C and 5% CO2, 
trypsinized and resuspended in a solution consisted of 50 
µM H2DCFA and 20 µg/mL PI. Samples were analyzed by 
flow cytometry and only PI-negative cells were used for 
ROS quantification.
Biochemical assays
The concentrations of glucose, lactate, glutamate 
and glutamine in culture medium were determined by 
spectrophotometry (COBAS Mira Plus, Horiba ABX) 
monitoring at 340 nm wavelength the production 
or consumption of NAD(P)H by specific enzymatic 
reactions for each metabolite. Glucose concentration 
was measured using the coupled enzymatic reactions 
of glucose-6-phosphate dehydrogenase and hexokinase 
(commercial enzymatic kit). The concentration of lactate 
was determined by the lactate dehydrogenase (LDH) 
reaction carried out at 37°C by adding a sample of media 
to a cuvette containing 1.55 mg/mL NAD+ and 87.7 
U/mL of LDH in 0.2 M hydrazine 12 mM EDTA buffer, 
pH 9. Determination of glutamate concentration was 
performed through the glutamate dehydrogenase (GLDH) 
reaction at 37 °C by adding a sample of media to a cuvette 
containing 2.41 mM ADP, 3.9 mM NAD+ and 39 U/mL 
of GLDH in 0.5 M glycine/0.5 M hydrazine buffer, pH 9. 
The concentration of glutamine was determined by its 
conversion first to glutamate through the glutaminase 
(GLS) reaction followed by the quantification of glutamate 
concentration as described above. GLS reaction was 
carried out for 90 min at 37°C with shaking by adding a 
sample of culture media to a cuvette containing a mixture 
consisted of 90 mU/mL GLS in 111 mM acetate buffer, 
pH 5. To calculate the consumption/production rate of 
each metabolite, samples of culture media were taken at 
the beginning and at the end of the experiment and stored 
at –20°C for subsequent analysis. In the same cell culture 
plates, or parallel plates when required, cell number was 
determined through the procedure described above for 
normalization.
[13C]-assisted metabolomics 
Cells were grown in full medium containing 50% 
of [1,2-13C2]-glucose (Sigma-Aldrich) for 24 hours. At 
the end of the experiment, media and cell pellets were 
collected. Medium samples were kept at –20°C for 
ulterior determination of the concentration of glucose, 
lactate, glutamate and glutamine and the isotopologue 
distributions of glucose, lactate and alanine. Pellets 
were obtained by trypsinization and kept at –20°C for 
subsequent analysis of the isotopologue distribution of 
ribose and fatty acids. The isotopologue distribution 
analyses of the polar metabolites were performed by gas 
chromatography coupled to mass spectrometry (GC-MS) 
using an Agilent 7890A GC equipped with a HP5 capillary 
column coupled to an Agilent 5975C MS. GCMS-QP 2012 
Shimadzu equipped with a bp × 70 (SGE) column was 
used for fatty acids analysis. In all cases, one microliter 
of sample was injected at 250°C using helium as carrier 
gas at a flow rate of 1 mL/min. Glucose was isolated 
from cell culture media using a tandem set of Dowex-
1X8/Dowex-50WX8 ion-exchange columns using water 
as eluent. Samples were then dried under airflow and 
2% (v/v) hydroxylamine hydrochloride in pyridine 
was added at 100°C for 30 min followed by addition of 
acetic anhydride for 1h. Samples were evaporated under 
N2 and dissolved in ethyl acetate. GC-MS analysis of 
glucose was performed under chemical ionization mode. 
Samples were injected at 250°C and oven temperature was 
held at 230°C for 2 min after injection and increased to 
260°C at 10°C/min. Glucose retention time (RT) was 
3.8 min. Detector was run in selected ion monitoring 
mode (SIM) and the ion abundance of the C1-C6 molecule 
(327–336 m/z) was recorded. Lactate was isolated from 
cell culture medium by acidification of samples with HCl, 
extraction with ethyl acetate and evaporation under N2. 
Next, dimethoxypropane and methanolic chloride were 
added for 1h at 75°C. After, samples were treated with 
n-propilamine for 1h at 100°C and dried under N2. The 
precipitate was then resuspended in dichloromethane and 
heptafluorobutyric anhydride at room temperature for 
10 min. After that, samples were dried and resuspended 
in dichloromethane. GC-MS analysis of lactate was 
performed under chemical ionization mode. Sample 
was injected at 200ºC and oven temperature was held at 
100°C for 3 min after injection and increased to 160°C 
at 20°C/min. Lactate RT was 5.4 min. Detector was run 
in SIM and the ion abundance of the C1-C3 molecule 
(327–332 m/z) was recorded. Alanine was isolated from 
cell culture medium by passing a sample of media through 
a Dowex-50WX8 (H+) column and eluted with 2 N 
NH4OH followed by evaporation under airflow. Samples 
were then incubated in butanolic HCl at 100°C for 1 h 
and subsequently dried under N2. The precipitate was then 
dissolved in dichloromethane and trifluoroacetic anhydride 
and incubated at room temperature for 20 min. Samples 
were dried under N2 and dissolved in dichloromethane. 
GC-MS analysis of alanine was performed under chemical 
ionization mode. Sample was injected at 250°C and oven 
temperature was held at 110°C for 1 min, increased to 
125°C at 10 °C/min, then to 153°C at 5°C/min, to 200°C 
at 50°C/min, to 216°C at 5°C/min and finally to 250°C at 
25°C/min. Alanine RT was 5.28 min. Detector was run in 
SIM and the ion abundance of the C1-C3 molecule (m/z 
241-246) was recorded. Ribose from RNA was isolated 
from cell pellets. After addition of Trizol® (Invitrogen), the 
aqueous phase was separated and RNA was hydrolyzed 
by addition of 2N HCl for 2h at 100°C. Samples were 
then dried under airflow and derivatized as previously 
described for glucose. GC-MS analysis of ribose was 
performed under chemical ionization mode. Sample 
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was injected at 250°C and oven temperature was held at 
150°C for 1 min after injection, increased to 275°C at 
15°C/min and finally to 300°C at 40°C/min. Ribose 
RT was 5.3 min. Detector was run in SIM and the ion 
abundance of the C1-C5 molecule (256–261 m/z) was 
recorded. Palmitate and stearate from cultured cells were 
extracted from the inter- and lower phase of the Trizol 
extract as described above by adding 100% ethanol and 
30% KOH. After that, samples were incubated at 70°C 
overnight. Then, free fatty acids were extracted by addition 
of petroleum ether and samples were dried under N2. Fatty 
acids were then derivatized by adding 0.5 N methanolic-
HCl at 70°C for 1h. GC-MS analysis of palmitate and 
stearate was performed under chemical ionization mode. 
Sample was injected at 250°C and oven temperature was 
held at 120°C for 1 min after injection and increased to 
220°C at 5°C/min. Detector was run in SIM and the ion 
abundance in the range of 269-278 m/z for palmitate (RT: 
9.2) and 297–307 m/z for stearate (RT:11.85) was recorded. 
Enzyme activities
Cells extracts were prepared using lysis buffer 
consisting of 20 mM Tris-HCl buffer, pH 7.5 supplemented 
with 1 mM DTT, 1 mM EDTA, 0.02% (v/v) Triton X-100, 
0.02% (v/v) sodium deoxycholate and protease inhibition 
cocktail (Sigma-Aldrich). Lysates were then disrupted 
by sonication using titanium probe (VibraCell, Sonics & 
Materials Inc.) and immediately centrifuged at 12,000 × g 
for 20 min at 4°C. The supernatant was used for the 
determination of the enzyme activities by monitoring 
changes in the concentration of NAD(P)H using a COBAS 
Mira Plus analyzer. Glucose-6-phosphate dehydrogenase 
activity (G6PD, EC 1.1.1.49.) was measured by adding 
the lysates to a cuvette containing 0.5 mM NADP+ in 
50 mM Tris-HCl buffer, pH 7.6, at 37°C. The reaction 
was initiated by the addition of glucose-6-phosphate up 
to a final concentration of 2 mM. Transketolase activity 
(TKT, EC 2.2.1.1.) was determined by adding the 
lysates to a cuvette containing 5 mM MgCl2, 0.2 U/mL 
of triose phosphate isomerase, 0.2 mM NADH and 0.1 
mM thiamine pyrophosphate in 50 mM Tris-HCl buffer, 
pH 7.6, at 37°C. The reaction was initiated by adding 
the resulting solution of the reaction of 50 mM ribose-5-
phosphate in 50 mM Tris-HCl buffer, pH 7.6, with 0.1 U/
mL of ribulose-5-phosphate-3-epimerase and 1.7 mU/mL 
of phosphoriboisomerase for 1h in agitation at 37ºC. 
Survival and correlation analysis
The Kaplan–Meier (KM) estimator was used to 
construct the survival curves. Survival analyses of the breast 
cancer datasets GSE20685 [51], GSE7390 [52], GSE3494 
[53] were performed through the online application KM 
plotter [54] and subsequently edited in GraphPad PRISM. 
Time to death and time to relapse were chosen as the events 
of interest to estimate the overall (OS) and relapse-free 
survival (RFS). In each cohort patients were separated 
into high and low expression of TKT and G6PD as 
reported by the JetSet probes [55] 208700_s_at (TKT) and 
202275_at (G6PD) by applying the best cutoff algorithm, 
which computes the KM estimator for each percentile 
of expression between the lower and upper quartiles and 
uses the best performing threshold as the final cutoff 
[56]. Statistical differences between survival curves were 
assessed by log-rank test and the corresponding p-values are 
indicated in each plot. Pearson’s correlation analyses were 
performed in PRISM using normalized TKT and G6PD 
expression values obtained from each dataset using the 
above-mentioned probe codes.
Statistical analyses
Results are expressed as mean ± SEM for multiple 
experiments or mean ± SD for individual experiments. 
Data was analyzed by one-way ANOVA followed by 
Dunetts’s post-test analysis for correction of multiple 
comparisons against the control condition (siNEG). 
GraphPad PRISM was used for generation of plots and 
statistical tests. * denotes adjusted p-value < 0.1 and ** 
p-value < 0.05.
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